The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Intravenous Immunoglobulin Treatment for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Prospective Noncomparative Study Showing No Benefit on Mortality or Progression
Open accessAbstract
BACKGROUND: It has been proposed that Fas-Fas ligand interaction was responsible for the apoptosis of epidermal cells in Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) and that high doses of intravenous immunoglobulin (IVIG) could help patients by blocking the apoptosis. OBJECTIVE: To study the effects of IVIG on SJS and TEN. DESIGN: Prospective open trial. SETTING: Referral center of a university hospital. PATIENTS: Thirty-four consecutive patients admitted for SJS (n = 9), SJS-TEN (n = 5), or TEN (n = 20) a mean of 4.3 days after onset. INTERVENTION: A dose of 2 g/kg of IVIG was administered within 2 days (half doses or full doses over a longer period for patients with low creatinine clearance). MAIN OUTCOME MEASURES: Detached plus detachable proportions of the total body surface area measured before and after treatment and predicted death rate estimated on admission with a validated prognostic score. RESULTS: Epidermal detachment involved a mean +/- SD 19% +/- 16% of the total body surface area on admission and 32% +/- 26% after IVIG treatment (progression in 22 of 34 cases, including most patients referred early). The prognostic score predicted 8.2 deaths (24%); 11 were observed (32%; 95% confidence interval, 17%-51%). Most deaths occurred in elderly patients who had initially impaired renal function. CONCLUSIONS: The confidence interval of the observed death rate excludes a dramatic decrease in mortality. No measurable effect was observed on the progression of detachment or on the speed of reepidermalization. These results do not support the routine use of IVIG treatment for patients with SJS or TEN, especially in cases of impaired renal function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Severe Adverse Cutaneous Reactions to Drugs
Roujeau, J. C., & Stern, R. S. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411103311906 · Cited by 1,571
Self-citationSCORTEN: A Severity-of-Illness Score for Toxic Epidermal Necrolysis
Fouchard, N., Bertocchi, M., Roujeau, J.-C., Revuz, J., Wolkenstein, P., & Bastuji-Garin, S. (2000) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2000.00061.x · Cited by 1,199
Self-citationInhibition of Toxic Epidermal Necrolysis by Blockade of CD95 with Human Intravenous Immunoglobulin
Viard, I., Wehrli, P., Bullani, R., Schneider, P., Holler, N., Salomon, D., Hunziker, T., Saurat, J.-H., Tschopp, J., & French, L. E. (1998) · Science · doi:10.1126/science.282.5388.490 · Cited by 1,005
Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin
(1999) · Transfusion Medicine Reviews · doi:10.1016/s0887-7963(99)80071-6 · Cited by 869
Death Receptors in Cutaneous Biology and Disease
Wehrli, P., Viard, I., Bullani, R. R., French, L. E., & Tschopp, J. (2000) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2000.00037.x · Cited by 139
Becker, D. S. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11369-1 · Cited by 138
High-dose intravenous IgG treatment and renal function
Schifferli, J. A., Leski, M., Favre, H., Imbach, P. A., Nydegger, U., & Davies, K. A. (1991) · The Lancet · doi:10.1016/0140-6736(91)93395-p · Cited by 92
Cited by
Drug Allergy: An Updated Practice Parameter
(2010) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2010.08.002 · Cited by 957
Toxic epidermal necrolysis and Stevens-Johnson syndrome
Harr, T., & French, L. E. (2010) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-5-39 · Cited by 693
ORANGE, J., HOSSNY, E., WEILER, C., BALLOW, M., BERGER, M., BONILLA, F., BUCKLEY, R., CHINEN, J., ELGAMAL, Y., & MAZER, B. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.01.015 · Cited by 653
Sicherer, S. H., & Sampson, H. A. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.05.048 · Cited by 647
Severe cutaneous adverse reactions to drugs
Duong, T. A., Valeyrie-Allanore, L., Wolkenstein, P., & Chosidow, O. (2017) · The Lancet · doi:10.1016/s0140-6736(16)30378-6 · Cited by 445
Metadata
- Authors
- Bachot, N., Revuz, J., & Roujeau, J.-C.
- Venue
- Archives of Dermatology
- Publisher
- American Medical Association (AMA)
- Published
- 2003-01-01
- Volume
- 139
- Issue
- 1
- Pages
- 33
- ISSN
- 0003-987X (ISSN-L)
- OpenAlex
- W2022250655
- Cited by
- 380
- References
- 8
- FWCI
- 18.16
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intravenous Immunoglobulin Treatment for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Prospective Noncomparative Study Showing No Benefit on Mortality or Progression. https://app.cochat.ai/papers/10.1001/archderm.139.1.33
- The paper
- Bachot, N., Revuz, J., & Roujeau, J.-C. (2003). Intravenous Immunoglobulin Treatment for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Prospective Noncomparative Study Showing No Benefit on Mortality or Progression. Archives of Dermatology. https://doi.org/10.1001/archderm.139.1.33
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.